A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies

Completed · Phase 1

Conditions studied: Advanced Nonhematologic Malignancies, Carcinoma, Basal Cell

In brief

This is the first study in which TAK-441 is administered to humans. The patient population will consist of adults aged 18 or older who have advanced nonhematologic malignancies and for whom standard treatment is no longer effective or does not offer curative or life-prolonging potential. Following completion of the dose escalation study, patients will be enrolled as part of 2 expansion cohorts.

Key facts

Study ID

NCT01204073

Run by

Millennium Pharmaceuticals, Inc.

People needed

34

Starts

2010-10-01

Expected to finish

2013-01-01

Last updated by the study team

2013-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Each patient must meet all of the following inclusion criteria to be enrolled in the study:
• Male or female 18 years or older
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
• Diagnosis of a nonhematologic malignancy for which standard treatment is no longer effective or does not offer curative or life-prolonging potential
• Meet other clinical, radiographic or laboratory inclusion criteria as specified in the protocol
• Voluntary written consent

You may not qualify if…

• Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
• Life-threatening illness unrelated to cancer
• Receiving other treatment (radiotherapy, antineoplastics or investigational agents) within protocol specified windows of first dose of TAK-441
• Patients with brain metastases who do not meet criteria specified in study protocol
• Known history of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
• Major surgery within 14 days before the first dose of TAK-441
• Infection requiring systemic therapy, or other serious infection within 14 days of the first dose of TAK-441
• Do not meet other clinical, laboratory or radiographic criteria as specified in the protocol

Where it is running

• Mayo Clinic — Scottsdale, Arizona, United States
• Premiere Oncology, A Medical Corporation — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.